GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $15.92 $21.60 Friday, 19th Apr 2024 DNLI stock ended at $16.00. This is 3.61% less than the trading day before Thursday, 18th Apr 2024. During the day the stock fluctuated 5.50% from a day low at $15.92 to a day high of $16.79.
90 days $15.52 $23.52
52 weeks $15.45 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
2024-04-19 $16.50 $16.79 $15.92 $16.00 1 479 839
2024-04-18 $16.72 $16.95 $16.54 $16.60 1 140 996
2024-04-17 $17.55 $17.56 $16.79 $16.82 1 310 639
2024-04-16 $17.59 $17.59 $17.16 $17.34 1 043 138
2024-04-15 $18.29 $18.29 $17.71 $17.84 909 393
2024-04-12 $18.97 $19.01 $17.84 $18.26 1 083 608
2024-04-11 $18.71 $19.20 $18.51 $19.17 870 643
2024-04-10 $18.57 $18.64 $18.05 $18.42 1 215 141
2024-04-09 $19.01 $19.75 $18.91 $19.44 635 740
2024-04-08 $19.60 $19.61 $18.89 $19.04 650 440
2024-04-05 $18.76 $19.42 $18.28 $19.39 734 927
2024-04-04 $19.53 $19.67 $18.95 $18.99 650 429
2024-04-03 $19.04 $19.40 $18.95 $19.37 726 723
2024-04-02 $20.02 $20.11 $19.21 $19.38 1 064 175
2024-04-01 $20.52 $20.75 $20.09 $20.56 663 506
2024-03-28 $20.86 $21.04 $20.12 $20.52 957 299
2024-03-27 $20.05 $20.92 $19.85 $20.77 767 593
2024-03-26 $20.14 $20.19 $19.47 $19.88 1 174 661
2024-03-25 $19.37 $19.96 $19.35 $19.87 913 574
2024-03-22 $20.98 $21.04 $19.58 $19.62 861 069
2024-03-21 $21.53 $21.60 $20.92 $21.00 1 117 921
2024-03-20 $20.34 $21.48 $20.16 $21.29 912 527
2024-03-19 $19.94 $20.62 $19.83 $20.54 951 681
2024-03-18 $20.10 $20.60 $19.77 $20.09 893 165
2024-03-15 $19.71 $20.35 $19.66 $20.13 2 108 786
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT